COVID-19 therapeutics and beyond: An HTS to identify inhibitors of SARS-CoV-2 nsp12 and starting points for other Coronavirus inhibitors

COVID-19 疗法及其他：识别 SARS-CoV-2 nsp12 抑制剂的 HTS 以及其他冠状病毒抑制剂的起点

• 批准号: MC_PC_21006
• 负责人: Richard Angell
• 金额: $ 16.37万
• 依托单位: University College London
• 依托单位国家: 英国
• 项目类别: Intramural
• 财政年份: 2021
• 资助国家: 英国
• 起止时间: 2021 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=MC_PC_21006
• 关键词: COVID; 19; therapeutics; beyond; HTS

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

GTR目前尚未用于所有资助研究的摘要。这通常是因为提交提案时不需要摘要，但可能是因为它包含了敏感信息，例如个人详细信息。